<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial regimens for the treatment of &lt;em&gt;Streptococcus anginosus&lt;/em&gt; group infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial regimens for the treatment of <em>Streptococcus anginosus</em> group infections</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial regimens for the treatment of <em>Streptococcus anginosus</em> group infections</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Adult dosing</td> <td class="subtitle1">Pediatric dosing</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Initial antimicrobial regimen*</td> </tr> <tr> <td class="indent1" rowspan="2">Preferred regimens</td> <td> <ul> <li>Ceftriaxone 2 g IV every 24 hours, <strong>or</strong></li> <li>Penicillin G 2 to 4 million units IV every 4 to 6 hours</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 500 mg orally or IV every 8 hours</li> </ul> </td> <td> <ul> <li>Ceftriaxone 50 to 100 mg/kg/<strong>dose</strong> IV every 24 hours (maximum: 1000 mg/<strong>dose</strong>), <strong>or</strong></li> <li>Penicillin G 100,000 to 300,000 units/kg/<strong>day</strong> IV divided every 4 to 6 hours (maximum dose: 24 million units/<strong>day</strong>)</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 30 to 40 mg/kg/<strong>day</strong> orally or IV in 3 divided doses (maximum: 500 mg/<strong>dose</strong>)</li> </ul> </td> </tr> <tr> <td> <ul> <li>Ampicillin-sulbactam<sup>¶</sup> 3 g IV every 6 hours</li> </ul> </td> <td> <ul> <li>Ampicillin-sulbactam<sup>¶</sup> 100 to 200 <strong>mg ampicillin</strong>/kg/<strong>day</strong> IV divided every 6 hours (maximum: 2000 mg ampicillin/<strong>dose</strong>)</li> </ul> </td> </tr> <tr> <td class="indent1" rowspan="2">Alternative regimens<br/> (for patients who cannot tolerate or have contraindications to preferred regimens)</td> <td> <ul> <li>For patients who require anti-anaerobic therapy: <ul> <li>Ertapenem 1 g IV every 24 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>For patients who require anti-anaerobic therapy: <ul> <li>Ertapenem <ul> <li>Children ≥3 months to &lt;13 years: 15 mg/kg/<strong>dose</strong> IV every 12 hours (maximum: 500 mg/<strong>dose</strong>)</li> <li>Children ≥13 years: 1 g IV every 24 hours</li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td> <ul> <li>For patients with endovascular infections without associated abscess: <ul> <li>Vancomycin IV<sup>Δ</sup> <strong>or</strong></li> <li>Linezolid 600 mg orally or IV every 12 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>For patients with endovascular infections without associated abscess: <ul> <li>Vancomycin IV<sup>◊</sup> <strong>or</strong></li> <li>Linezolid <ul> <li>Children &lt;12 years: 10 mg/kg/<strong>dose</strong> orally or IV every 8 hours (maximum: 600 mg/<strong>dose</strong>)</li> <li>Children ≥12 years: 600 mg orally or IV every 12 hours</li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Oral step-down regimens for select cases<sup>§</sup></td> </tr> <tr> <td class="indent1" rowspan="2">Preferred regimens</td> <td> <ul> <li>Amoxicillin-clavulanate 875 mg/125 mg orally 2 to 3 times daily</li> </ul> </td> <td> <ul> <li>Amoxicillin-clavulanate<sup>¥</sup> 45 <strong>mg amoxicillin</strong>/kg/<strong>day</strong> orally in 2 divided doses (maximum: 1750 mg/<strong>day</strong>)</li> </ul> </td> </tr> <tr> <td> <ul> <li>Cefuroxime 500 mg orally twice daily</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 500 mg orally 3 times daily, <strong>or</strong></li> <li>Clindamycin 300 mg orally 4 times daily or 300 to 450 mg orally 3 times daily</li> </ul> </td> <td> <ul> <li>Cefuroxime 20 to 30 mg/kg/<strong>day</strong> orally in 2 divided doses (mild to moderate infection, maximum: 500 mg/<strong>dose</strong>)</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 30 to 40 mg/kg/<strong>day</strong> orally in 3 divided doses (maximum: 500 mg/<strong>dose</strong>), <strong>or</strong></li> <li>Clindamycin 10 to 25 mg/kg/<strong>day</strong> orally in 3 divided doses (maximum: 1800 mg/<strong>day</strong>)</li> </ul> </td> </tr> <tr> <td class="indent1">Alternative regimens<br/> (for patients who cannot tolerate or have contraindications to preferred regimens)</td> <td> <ul> <li>Linezolid 600 mg orally twice daily</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Ciprofloxacin 500 mg orally twice daily</li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 500 mg orally every 8 hours, <strong>or</strong></li> <li>Clindamycin 300 mg orally 4 times daily or 300 to 450 mg orally 3 times daily</li> </ul> </td> <td> <ul> <li>Linezolid <ul> <li>Children &lt;12 years: 10 mg/kg/<strong>dose</strong> orally every 8 hours (maximum: 600 mg/<strong>dose</strong>)</li> <li>Children ≥12 years: 600 mg orally twice daily</li> </ul> </li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Ciprofloxacin 10 to 15 mg/kg/<strong>dose</strong> orally twice daily (maximum: 500 mg/<strong>dose</strong>)<sup>‡</sup></li> </ul> <p class="extra_spacing"><strong>PLUS</strong></p> <ul> <li>Metronidazole 30 to 40 mg/kg/<strong>day</strong> orally in 3 divided doses (maximum: 500 mg/<strong>dose</strong>), <strong>or</strong></li> <li>Clindamycin 10 to 25 mg/kg/<strong>day</strong> orally in 3 divided doses (maximum: 1800 mg/<strong>day</strong>)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Selected antimicrobial regimens are listed here. Other regimens with the same spectrum of activity are also appropriate. The doses recommended in this table are intended for patients with normal kidney and liver function. Pediatric dosing is intended for patients &gt;28 days of age, unless otherwise noted. Refer to Lexicomp drug monographs and the UpToDate clinical topic review of <em>S. anginosus</em> group infections for additional information.</div><div class="graphic_footnotes"><p>IV: intravenously.</p>
<p>* Dosing of certain antimicrobials (eg, ceftriaxone, penicillin G, ampicillin, clindamycin) for treatment of severe infections (eg, central nervous system infections, endocarditis) differs from the doses listed in this table. Refer to Lexicomp drug monographs.</p>
<p>¶ Ampicillin-sulbactam is a combination product formulated in a 2:1 ratio (eg, each vial contains 2 g of ampicillin and 1 g of sulbactam). Adult dosing is provided as total grams of ampicillin and sulbactam. Pediatric dosing is expressed as mg of ampicillin component.</p>
<p>Δ For severely ill patients, a vancomycin loading dose (20 to 35 mg/kg) is appropriate; within this range, we use a higher dose for critically ill patients. The loading dose is based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg. The initial maintenance dose and interval are determined by nomogram (typically 15 to 20 mg/kg every 8 to 12 hours for most patients with normal kidney function). Subsequent dose and interval adjustments are based on area under the curve (AUC)-guided or trough-guided serum concentration monitoring. Refer to the UpToDate topic on vancomycin dosing for sample nomogram and discussion of vancomycin monitoring.</p>
<p>◊ The approach to pediatric vancomycin dosing is generally determined at the institutional level. A typical dose is 15 mg/kg/<strong>dose</strong> IV every 6 to 8 hours (use every 6-hour interval for serious infections; maximum dose: 4 g/<strong>day</strong>), however other dosing strategies (eg, AUC-guided approach) may be used. Refer to UpToDate content on invasive staphylococcal infections in children for details of trough-guided and AUC-guided vancomycin dosing.</p>
<p>§ Oral step-down therapy is appropriate for certain clinical syndromes (eg, abscess in the absence of bacteremia). However, we favor continuing initial intravenous therapy for endovascular infections (eg, bacteremia, endocarditis) as well as other severe or difficult to treat syndromes.</p>
<p>¥ Dosing is based on the amoxicillin component for the amoxicillin:clavulanate 7:1 formulations (eg, amoxicillin-clavulanate 200 mg/28.5 mg, 400 mg/57 mg, or 875 mg/125 mg). Not all products are interchangeable; using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or adverse effects (eg, severe diarrhea). For dosing for other amoxicillin-clavulanate formulations, refer to the Lexicomp drug monograph.</p>
‡ Although ciprofloxacin is not routinely used in children, it is a reasonable alternative when no other oral options are available.</div><div id="graphicVersion">Graphic 139420 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
